169883-27-6

Upstream product

• 53925-27-2 2-methyl-4,6-dihydroxy-5-nitropyrimidine 
• 82779-50-8 4,6-dichloro-2-methyl-5-nitropyrimidine 
• 1194-22-5 2-methyl-4,6-dihydroxypyrimidine 
• 51605-97-1 2-bromo-4-isopropylaniline 
• 39906-04-2 5-amino-4,6-dichloro-2-methylpyrimidine 

Downstream Products

• 169882-27-3 9-<2-bromo-4-(1-methylethyl)phenyl>-6-chloro-2-methyl-9H-imidazo<4,5-d>pyrimidine 
• 169882-29-5 3-[2-bromo-4-(1-methylethyl)phenyl]-7-chloro-5-methyl-3H-1,2,3-triazolo[4,5-d]pyrimidine 
• 228559-10-2 9-(2-bromo-4-isopropyl-phenyl)-6-(butyl-ethyl-amino)-2-methyl-7,9-dihydro-purin-8-one 

Relevant academic research and scientific papers

Certain alkylene diamine-substituted heterocycles

The present invention also provides a general method to whereby mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1receptor. The present invention provides novel, potent, non-peptidic antagonists of NP

1N-ALKYL-N-ARYLPYRIMIDINAMINES AND DERIVATIVES THEREOF

The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer'disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R 1, R 3, R 4, R 5, Z, Y, V, X, X', J, K, L, and M are as defined herein.

Arylamino fused pyrimidines

Corticotropin releasing factor (CRF) antagonists of formula I or formula II: and their use in treating anxiety, depression, and other psychiatric and neurological disorders.

Purin-8-ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists

A series of purin-8-ones was prepared and discovered to have excellent binding affinity to the CRH-R1 receptor. Structure-activity studies focused on amine side-chain optimization, urea substitution and pyridyl isostere incorporation. Thus, the highly potent purin-8-ones show promise as a new class of potential anxiolytics and/or antidepressants.

Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines

The synthesis and CRF receptor binding affinities of several new series of N-aryltriazolo- and -imidazopyrimidines and -pyridines are described. These cyclized systems were prepared from appropriately substituted diaminopyrimidines or -pyridines by nitrous acid, orthoester, or acyl halide treatment. Variations of amino (ether) pendants and aromatic substituents have defined the structure-activity relationships of these series and resulted in the identification of a variety of high-affinity agents (K(i)'s 1 has been selected for further pharmacological studies that will be reported in due course.